Prognostic value of serum CD44, intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 levels in patients with indolent non-Hodgkin lymphomas

References

• Ansell SM, Armitage J. Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 2005;80:1087–1097.
   PubMed Web of Science ®Google Scholar
• Lopez-Guillermo A, Montserrat E, Bosch F, . Applicability of the International Index for aggressive lymphomas to patients with low-grade lymphoma. J Clin Oncol 1994;12:1343–1348.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Roy P, Colombat P, . Follicular lymphoma international prognostic index. Blood 2004;104:1258–1265.
   PubMed Web of Science ®Google Scholar
• Federico M, Bellei M, Marcheselli L, . Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. J Clin Oncol 2009;27:4555–4562.
   PubMed Web of Science ®Google Scholar
• Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000;95:1900–1910.
   PubMed Web of Science ®Google Scholar
• Gribben JG. Implications of the tumor microenvironment on survival and disease response in follicular lymphoma. Curr Opin Oncol 2010;22:424–430.
   PubMed Web of Science ®Google Scholar
• Naor D, Wallach-Dayan SB, Zahalka MA, . Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008;18:260–267.
   PubMed Web of Science ®Google Scholar
• Screaton GR, Bell MV, Jackson DG, . Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160–12164.
   PubMed Web of Science ®Google Scholar
• Gal I, Lesley J, Ko W, . Role of the extracellular and cytoplasmic domains of CD44 in the rolling interaction of lymphoid cells with hyaluronan under physiologic flow. J Biol Chem 2003;278: 11150–11158.
   PubMed Web of Science ®Google Scholar
• Herrlich P, Morrison H, Sleeman J, . CD44 acts both as a growth- and invasiveness-promoting molecule and as a tumor-suppressing cofactor. Ann NY Acad Sci 2000;910:106–118; discussion 118–120.
   PubMed Web of Science ®Google Scholar
• Bartolazzi A, Peach R, Aruffo A, . Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994;180:53–66.
   PubMed Web of Science ®Google Scholar
• Wielenga VJ, Heider KH, Offerhaus GJ, . Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993;53:4754–4756.
   PubMed Web of Science ®Google Scholar
• Tacyildiz N, Cavdar AO, Yavuz G, . Serum levels and differential expression of CD44 in childhood leukemia and malignant lymphoma: correlation with prognostic criteria and survival. Pediatr Int 2001;43:354–360.
   PubMed Web of Science ®Google Scholar
• Niitsu N, Iijima K. High serum soluble CD44 is correlated with a poor outcome of aggressive non-Hodgkin's lymphoma. Leuk Res 2002;26:241–248.
   PubMed Web of Science ®Google Scholar
• Sasaki K, Niitsu N. Elevated serum levels of soluble CD44 variant 6 are correlated with shorter survival in aggressive non-Hodgkin's lymphoma. Eur J Haematol 2000;65:195–202.
   PubMed Web of Science ®Google Scholar
• Holland J, Owens T. Signaling through intercellular adhesion molecule 1 (ICAM-1) in a B cell lymphoma line. The activation of Lyn tyrosine kinase and the mitogen-activated protein kinase pathway. J Biol Chem 1997;272:9108–9112.
   PubMed Web of Science ®Google Scholar
• Lalancette M, Aoudjit F, Potworowski EF, . Resistance of ICAM-1-deficient mice to metastasis overcome by increased aggressiveness of lymphoma cells. Blood 2000;95:314–319.
   PubMed Web of Science ®Google Scholar
• Abdelrazik N, Fouda M, Zaghloul MH, . Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma. Med Princ Pract 2008;17:233–238.
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Salgami E, Karayiannakis AJ, . Prognostic significance of soluble adhesion molecules in Hodgkin's disease. Anticancer Res 2004;24:1243–1247.
   PubMed Web of Science ®Google Scholar
• Terol MJ, Tormo M, Martinez-Climent JA, . Soluble intercellular adhesion molecule-1 (s-ICAM-1/s-CD54) in diffuse large B-cell lymphoma: association with clinical characteristics and outcome. Ann Oncol 2003;14:467–474.
   PubMed Web of Science ®Google Scholar
• Deem TL, Abdala-Valencia H, Cook-Mills JM. VCAM-1 activation of endothelial cell protein tyrosine phosphatase 1B. J Immunol 2007;178:3865–3873.
   Google Scholar
• Christiansen I, Sundstrom C, Kalkner KM, . Serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1) are elevated in advanced stages of non-Hodgkin's lymphomas. Eur J Haematol 1999;62:202–209.
   PubMedGoogle Scholar
• Hatzistilianou M, Athanassiadou F, Agguridaki C, . Circulating soluble adhesion molecule levels in children with acute lymphoblastic leukaemia. Eur J Pediatr 1997;156:537–540.
   PubMed Web of Science ®Google Scholar
• Christiansen I, Sundstrom C, Enblad G, . Soluble vascular cell adhesion molecule-1 (sVCAM-1) is an independent prognostic marker in Hodgkin's disease. Br J Haematol 1998;102:701–709.
   PubMed Web of Science ®Google Scholar
• Loeffler-Ragg J, Germing U, Sperr WR, . Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes. Crit Rev Oncol Hematol 2011;78:150–161.
   PubMed Web of Science ®Google Scholar
• Fabris C, Falleti E, Pirisi M, . Non-specific increase of serum carbohydrate antigen 19-9 in patients with liver disease associated with increased circulating levels of adhesion molecules. Clin Chim Acta 1995;243:25–33.
   PubMed Web of Science ®Google Scholar
• Chen C, Chang MC, Hsieh RK, . Activation of CD44 facilitates DNA repair in T-cell lymphoma but has differential effects on apoptosis induced by chemotherapeutic agents and ionizing radiation. Leuk Lymphoma 2005;46:1785–1795.
   PubMed Web of Science ®Google Scholar
• Aboul-Enein M, El-Sayed GM, El-Maghraby S, . Intercellular adhesion molecule-1(ICAM-1), CD44s expression and serum level of sICAM-1 in disseminated non-Hodgkin's lymphoma: correlation with overall survival. J Egypt Natl Canc Inst 2004;16:244–251.
   PubMedGoogle Scholar
• Weekes CD, Kuszynski CA, Sharp JG. VLA-4 mediated adhesion to bone marrow stromal cells confers chemoresistance to adherent lymphoma cells. Leuk Lymphoma 2001;40:631–645.
   PubMed Web of Science ®Google Scholar
• Christiansen I, Gidlof C, Wallgren AC, . Serum levels of soluble intercellular adhesion molecule 1 are increased in chronic B-lymphocytic leukemia and correlate with clinical stage and prognostic markers. Blood 1994;84:3010–3016.
   PubMed Web of Science ®Google Scholar
• Perez-Encinas M, Quintas A, Bendana A, . Correlation and prognostic value of serum soluble ICAM-1, beta-2 microglobulin, and IL-2alphaR levels in non-Hodgkin's lymphoma. Leuk Lymphoma 1999;33:551–558.
   PubMed Web of Science ®Google Scholar
• Christiansen I, Enblad G, Kalkner KM, . Soluble ICAM-1 in Hodgkin's disease: a promising independent predictive marker for survival. Leuk Lymphoma 1995;19:243–251.
   PubMed Web of Science ®Google Scholar
• Fukuda Y. Clinical significance of serum CD44 measurement in malignant lymphoma. Kurume Med J 2001;48:65–69.
   PubMedGoogle Scholar
• Maenpaa H, Ristamaki R, Virtamo J, . Serum CD44 levels preceding the diagnosis of non-Hodgkin's lymphoma. Leuk Lymphoma 2000;37:585–592.
   PubMed Web of Science ®Google Scholar
• Orian-Rousseau V. CD44, a therapeutic target for metastasising tumours. Eur J Cancer 2010;46:1271–1277.
   PubMed Web of Science ®Google Scholar
• DeLisser HM. CD44: target for antiangiogenesis therapy. Blood 2009;114:5114–5115.
   PubMed Web of Science ®Google Scholar
• Alkhamesi NA, Ziprin P, Pfistermuller K, . ICAM-1 mediated peritoneal carcinomatosis, a target for therapeutic intervention. Clin Exp Metastasis 2005;22:449–459.
   PubMed Web of Science ®Google Scholar
• Textor S, Accardi R, Havlova T, . NF-kappa B-dependent upregulation of ICAM-1 by HPV16-E6/E7 facilitates NK cell/target cell interaction. Int J Cancer 2011;128:1104–1113.
   PubMed Web of Science ®Google Scholar
• Lebedeva T, Dustin ML, Sykulev Y. ICAM-1 co-stimulates target cells to facilitate antigen presentation. Curr Opin Immunol 2005;17:251–258.
   PubMed Web of Science ®Google Scholar
• Slavin-Chiorini DC, Catalfamo M, Kudo-Saito C, . Amplification of the lytic potential of effector/memory CD8 + cells by vector-based enhancement of ICAM-1 (CD54) in target cells: implications for intratumoral vaccine therapy. Cancer Gene Ther 2004;11:665–680.
   PubMed Web of Science ®Google Scholar
• Gosk S, Moos T, Gottstein C, . VCAM-1 directed immunoliposomes selectively target tumor vasculature in vivo. Biochim Biophys Acta 2008;1778:854–863.
   PubMed Web of Science ®Google Scholar
• Morito T, Fujihara M, Asaoku H, . Serum soluble interleukin-2 receptor level and immunophenotype are prognostic factors for patients with diffuse large B-cell lymphoma. Cancer Sci 2009;100: 1255–1260.
   PubMed Web of Science ®Google Scholar
• Martin W, Abraham R, Shanafelt T, . Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Transl Res 2007;149:231–235.
   PubMed Web of Science ®Google Scholar
• Iqbal J, Liu Z, Deffenbacher K, . Gene expression profiling in lymphoma diagnosis and management. Best Pract Res Clin Haematol 2009;22:191–210.
   PubMed Web of Science ®Google Scholar
• Seki R, Ohshima K, Fujisaki T, . Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era. Cancer Sci 2009;100:1842–1847.
   PubMed Web of Science ®Google Scholar
• Zhang MZ, Sun ZC, Fu XR, . Analysis of serum proteome profiles of non-Hodgkin lymphoma for biomarker identification. J Proteomics 2009;72:952–959.
   PubMed Web of Science ®Google Scholar